{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:37:50Z","timestamp":1793759870535,"version":"4.6.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["MD-PhD\/Medical Scientist Training Program"],"award-info":[{"award-number":["MD-PhD\/Medical Scientist Training Program"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2024-00439841"],"award-info":[{"award-number":["RS-2024-00439841"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00452509"],"award-info":[{"award-number":["RS-2024-00452509"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Handok Inc"},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"crossref","award":["RS-2025-25459146"],"award-info":[{"award-number":["RS-2025-25459146"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministry of Health & Welfare, Republic of Korea","award":["HA22C0086"],"award-info":[{"award-number":["HA22C0086"]}]},{"DOI":"10.13039\/501100003645","name":"National Cancer Center, Korea","doi-asserted-by":"crossref","award":["NCC-1810861"],"award-info":[{"award-number":["NCC-1810861"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Biol"],"DOI":"10.1186\/s13059-026-04053-7","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:02:21Z","timestamp":1776117741000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Proteogenomic decoding of chemotherapy resistance in patients with triple-negative breast cancer"],"prefix":"10.1186","volume":"27","author":[{"given":"Dong Ki","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seul-Gi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Ji","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geon-Uk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Myoung","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Dong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Ju","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gun Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Bae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja Seung","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Ye","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Seok","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heon Yung","family":"Gee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joohyuk","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"4053_CR1","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938\u201348.","journal-title":"N Engl J Med"},{"key":"4053_CR2","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429\u201334.","journal-title":"Clin Cancer Res"},{"key":"4053_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami P, Carey LA. Triple negative breast cancer: pitfalls and progress. NPJ Breast Cancer. 2022;8:95.","journal-title":"NPJ Breast Cancer"},{"key":"4053_CR4","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750\u201367.","journal-title":"J Clin Invest"},{"key":"4053_CR5","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","volume":"21","author":"MD Burstein","year":"2015","unstructured":"Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21:1688\u201398.","journal-title":"Clin Cancer Res"},{"key":"4053_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"YZ Jiang","year":"2019","unstructured":"Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35:428-440.e425.","journal-title":"Cancer Cell"},{"key":"4053_CR7","doi-asserted-by":"publisher","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-13-0799","volume":"19","author":"H Masuda","year":"2013","unstructured":"Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19:5533\u201340.","journal-title":"Clin Cancer Res"},{"key":"4053_CR8","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/jnci\/djab004","volume":"113","author":"LA Emens","year":"2021","unstructured":"Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Di\u00e9ras V, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study. J Natl Cancer Inst. 2021;113:1005\u201316.","journal-title":"J Natl Cancer Inst"},{"key":"4053_CR9","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1200\/JCO.22.00069","volume":"40","author":"F Andre","year":"2022","unstructured":"Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022;40:1816\u201337.","journal-title":"J Clin Oncol"},{"key":"4053_CR10","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1200\/JCO.21.00976","volume":"39","author":"IA Mayer","year":"2021","unstructured":"Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, et al. Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131. J Clin Oncol. 2021;39:2539\u201351.","journal-title":"J Clin Oncol"},{"key":"4053_CR11","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","volume":"36","author":"TA Traina","year":"2018","unstructured":"Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O\u2019Shaughnessy J, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol. 2018;36:884\u201390.","journal-title":"J Clin Oncol"},{"key":"4053_CR12","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1158\/1078-0432.CCR-19-2170","volume":"26","author":"BD Lehmann","year":"2020","unstructured":"Lehmann BD, Abramson VG, Sanders ME, Mayer EL, Haddad TC, Nanda R, et al. TBCRC 032 IB\/II multicenter study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR(+) metastatic triple-negative breast cancer. Clin Cancer Res. 2020;26:2111\u201323.","journal-title":"Clin Cancer Res"},{"key":"4053_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15:121.","journal-title":"J Hematol Oncol"},{"key":"4053_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01850-7","volume":"22","author":"Y Liu","year":"2023","unstructured":"Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J, et al. Advances in immunotherapy for triple-negative breast cancer. Mol Cancer. 2023;22:145.","journal-title":"Mol Cancer"},{"key":"4053_CR15","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810\u201321.","journal-title":"N Engl J Med"},{"key":"4053_CR16","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, K\u00fcmmel S, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556\u201367.","journal-title":"N Engl J Med"},{"key":"4053_CR17","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39:1485\u2013505.","journal-title":"J Clin Oncol"},{"key":"4053_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/PPO.0000000000000498","volume":"27","author":"A Marra","year":"2021","unstructured":"Marra A, Curigliano G. Adjuvant and neoadjuvant treatment of triple-negative breast cancer with chemotherapy. Cancer J. 2021;27:41\u20139.","journal-title":"Cancer J"},{"key":"4053_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","volume":"2","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. Pd-l1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2:361\u201370.","journal-title":"Cancer Immunol Res"},{"key":"4053_CR20","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, et al. Homologous Recombination Deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22:3764\u201373.","journal-title":"Clin Cancer Res"},{"key":"4053_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/14737140.2021.1840984","volume":"21","author":"J Sukumar","year":"2021","unstructured":"Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Rev Anticancer Ther. 2021;21:135\u201348.","journal-title":"Expert Rev Anticancer Ther"},{"key":"4053_CR22","doi-asserted-by":"publisher","first-page":"e0157368","DOI":"10.1371\/journal.pone.0157368","volume":"11","author":"BD Lehmann","year":"2016","unstructured":"Lehmann BD, Jovanovi\u0107 B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11:e0157368.","journal-title":"PLoS One"},{"key":"4053_CR23","doi-asserted-by":"publisher","first-page":"11479","DOI":"10.1038\/ncomms11479","volume":"7","author":"B Pereira","year":"2016","unstructured":"Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479.","journal-title":"Nat Commun"},{"key":"4053_CR24","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.18.01010","volume":"37","author":"S Loi","year":"2019","unstructured":"Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019;37:559\u201369.","journal-title":"J Clin Oncol"},{"key":"4053_CR25","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1158\/2159-8290.CD-22-0200","volume":"12","author":"M Anurag","year":"2022","unstructured":"Anurag M, Jaehnig EJ, Krug K, Lei JT, Bergstrom EJ, Kim BJ, et al. Proteogenomic markers of chemotherapy resistance and response in triple-negative breast cancer. Cancer Discov. 2022;12:2586\u2013605.","journal-title":"Cancer Discov"},{"key":"4053_CR26","doi-asserted-by":"crossref","unstructured":"Chakraborty B, Byemerwa J, Shepherd J, Haines CN, Baldi R, Gong W, et al. Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma. J Clin Invest. 2021;131:23.","DOI":"10.1172\/JCI151347"},{"key":"4053_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"key":"4053_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110460","volume":"38","author":"TQ Gong","year":"2022","unstructured":"Gong TQ, Jiang YZ, Shao C, Peng WT, Liu MW, Li DQ, et al. Proteome-centric cross-omics characterization and integrated network analyses of triple-negative breast cancer. Cell Rep. 2022;38:110460.","journal-title":"Cell Rep"},{"key":"4053_CR29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0006-8993(01)02161-8","volume":"898","author":"MA Ansonoff","year":"2001","unstructured":"Ansonoff MA, Etgen AM. Estrogen increases G protein coupled receptor kinase 2 in the cortex of female rats. Brain Res. 2001;898:186\u20139.","journal-title":"Brain Res"},{"key":"4053_CR30","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ebiom.2016.09.030","volume":"13","author":"L Nogu\u00e9s","year":"2016","unstructured":"Nogu\u00e9s L, Reglero C, Rivas V, Salcedo A, Lafarga V, Neves M, et al. G protein-coupled receptor kinase 2 (GRK2) promotes breast tumorigenesis through a HDAC6-Pin1 axis. EBioMedicine. 2016;13:132\u201345.","journal-title":"EBioMedicine"},{"key":"4053_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34000-6","volume":"13","author":"D Zimmerli","year":"2022","unstructured":"Zimmerli D, Brambillasca CS, Talens F, Bhin J, Linstra R, Romanens L, et al. MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling. Nat Commun. 2022;13:6579.","journal-title":"Nat Commun"},{"key":"4053_CR32","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8707053","volume":"2019","author":"MV Giuli","year":"2019","unstructured":"Giuli MV, Giuliani E, Screpanti I, Bellavia D, Checquolo S. Notch signaling activation as a hallmark for triple-negative breast cancer subtype. J Oncol. 2019;2019:8707053.","journal-title":"J Oncol"},{"key":"4053_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01248","volume":"9","author":"K Zhang","year":"2018","unstructured":"Zhang K, Liu P, Tang H, Xie X, Kong Y, Song C, et al. AFAP1-AS1 promotes epithelial-mesenchymal transition and tumorigenesis through Wnt\/\u03b2-catenin signaling pathway in triple-negative breast cancer. Front Pharmacol. 2018;9:1248.","journal-title":"Front Pharmacol"},{"key":"4053_CR34","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/s43018-021-00282-w","volume":"2","author":"Z Hu","year":"2021","unstructured":"Hu Z, Yuan J, Long M, Jiang J, Zhang Y, Zhang T, et al. The cancer surfaceome atlas integrates genomic, functional and drug response data to identify actionable targets. Nat Cancer. 2021;2:1406\u201322.","journal-title":"Nat Cancer"},{"key":"4053_CR35","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.4049\/jimmunol.1600244","volume":"197","author":"M Boucard-Jourdin","year":"2016","unstructured":"Boucard-Jourdin M, Kugler D, Endale Ahanda ML, This S, De Calisto J, Zhang A, et al. \u03b28 integrin expression and activation of TGF-\u03b2 by intestinal dendritic cells are determined by both tissue microenvironment and cell lineage. J Immunol. 2016;197:1968\u201378.","journal-title":"J Immunol"},{"key":"4053_CR36","doi-asserted-by":"publisher","first-page":"e122591","DOI":"10.1172\/jci.insight.122591","volume":"3","author":"N Takasaka","year":"2018","unstructured":"Takasaka N, Seed RI, Cormier A, Bondesson AJ, Lou J, Elattma A, et al. Integrin \u03b1v\u03b28-expressing tumor cells evade host immunity by regulating TGF-\u03b2 activation in immune cells. JCI Insight. 2018;3:e122591.","journal-title":"JCI Insight"},{"key":"4053_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26352-2","volume":"12","author":"A Lain\u00e9","year":"2021","unstructured":"Lain\u00e9 A, Labiad O, Hernandez-Vargas H, This S, Sanlaville A, L\u00e9on S, et al. Regulatory T cells promote cancer immune-escape through integrin \u03b1v\u03b28-mediated TGF-\u03b2 activation. Nat Commun. 2021;12:6228.","journal-title":"Nat Commun"},{"key":"4053_CR38","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","volume":"163","author":"G Ciriello","year":"2015","unstructured":"Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 2015;163:506\u201319.","journal-title":"Cell"},{"key":"4053_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0317-1","volume":"14","author":"DA Nymoen","year":"2015","unstructured":"Nymoen DA, Holth A, Hetland Falkenthal TE, Trop\u00e9 CG, Davidson B. CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma. Mol Cancer. 2015;14:44.","journal-title":"Mol Cancer"},{"key":"4053_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-381","volume":"12","author":"AD Heibein","year":"2012","unstructured":"Heibein AD, Guo B, Sprowl JA, Maclean DA, Parissenti AM. Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization. BMC Cancer. 2012;12:381.","journal-title":"BMC Cancer"},{"key":"4053_CR41","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1038\/s41388-021-01711-x","volume":"40","author":"M Jalalirad","year":"2021","unstructured":"Jalalirad M, Haddad TC, Salisbury JL, Radisky D, Zhang M, Schroeder M, et al. Aurora-A kinase oncogenic signaling mediates TGF-\u03b2-induced triple-negative breast cancer plasticity and chemoresistance. Oncogene. 2021;40:2509\u201323.","journal-title":"Oncogene"},{"key":"4053_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58509-8","volume":"16","author":"L Ratinho","year":"2025","unstructured":"Ratinho L, Meyer N, Greive S, Cressiot B, Pelta J. Nanopore sensing of protein and peptide conformation for point-of-care applications. Nat Commun. 2025;16:3211.","journal-title":"Nat Commun"},{"key":"4053_CR43","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.cell.2020.10.036","volume":"183","author":"K Krug","year":"2020","unstructured":"Krug K, Jaehnig EJ, Satpathy S, Blumenberg L, Karpova A, Anurag M, et al. Proteogenomic landscape of breast cancer tumorigenesis and targeted therapy. Cell. 2020;183:1436-1456.e1431.","journal-title":"Cell"},{"key":"4053_CR44","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1007\/s00268-010-0683-1","volume":"34","author":"SPL Leong","year":"2010","unstructured":"Leong SPL, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik N-S, et al. Is breast cancer the same disease in Asian and Western countries? World J Surg. 2010;34:2308\u201324.","journal-title":"World J Surg"},{"key":"4053_CR45","doi-asserted-by":"publisher","first-page":"e2342107","DOI":"10.1001\/jamanetworkopen.2023.42107","volume":"6","author":"M Takahashi","year":"2023","unstructured":"Takahashi M, Cort\u00e9s J, Dent R, Pusztai L, McArthur H, K\u00fcmmel S, et al. Pembrolizumab plus chemotherapy followed by pembrolizumab in patients with early triple-negative breast cancer: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2023;6:e2342107.","journal-title":"JAMA Netw Open"},{"key":"4053_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032969","volume":"24","author":"NS van den Ende","year":"2023","unstructured":"van den Ende NS, Nguyen AH, Jager A, Kok M, Debets R, van Deurzen CHM. Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review. Int J Mol Sci. 2023;24:2969.","journal-title":"Int J Mol Sci"},{"key":"4053_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020228","volume":"17","author":"E B\u0142aszczak","year":"2025","unstructured":"B\u0142aszczak E, Miziak P, Odrzywolski A, Baran M, Gumbarewicz E, Stepulak A. Triple-negative breast cancer progression and drug resistance in the context of epithelial-mesenchymal transition. Cancers (Basel). 2025;17:228.","journal-title":"Cancers (Basel)"},{"key":"4053_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112358","volume":"9","author":"O Treeck","year":"2020","unstructured":"Treeck O, Sch\u00fcler-Toprak S, Ortmann O. Estrogen actions in triple-negative breast cancer. Cells. 2020;9:2358.","journal-title":"Cells"},{"key":"4053_CR49","doi-asserted-by":"publisher","first-page":"5209","DOI":"10.1038\/s41467-021-25322-y","volume":"12","author":"I Malenica","year":"2021","unstructured":"Malenica I, Adam J, Corgnac S, Mezquita L, Auclin E, Damei I, et al. Integrin-\u03b1(V)-mediated activation of TGF-\u03b2 regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade. Nat Commun. 2021;12:5209.","journal-title":"Nat Commun"},{"key":"4053_CR50","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1158\/1535-7163.MCT-22-0817","volume":"22","author":"RP Lyon","year":"2023","unstructured":"Lyon RP, Jonas M, Frantz C, Trueblood ES, Yumul R, Westendorf L, et al. SGN-B6A: a new vedotin antibody-drug conjugate directed to integrin beta-6 for multiple carcinoma indications. Mol Cancer Ther. 2023;22:1444\u201353.","journal-title":"Mol Cancer Ther"},{"key":"4053_CR51","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40\u201350.","journal-title":"Lancet Oncol"},{"key":"4053_CR52","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.annonc.2024.10.012","volume":"36","author":"M Mart\u00edn","year":"2025","unstructured":"Mart\u00edn M, Stecklein SR, Gluz O, Villacampa G, Monte-Mill\u00e1n M, Nitz U, et al. TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy. Ann Oncol. 2025;36:158\u201371.","journal-title":"Ann Oncol"},{"key":"4053_CR53","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ajpath.2019.10.018","volume":"190","author":"R Pichler","year":"2020","unstructured":"Pichler R, Lindner AK, Comp\u00e9rat E, Obrist P, Sch\u00e4fer G, Todenh\u00f6fer T, et al. Amplification of 7p12 is associated with pathologic nonresponse to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Am J Pathol. 2020;190:442\u201352.","journal-title":"Am J Pathol"},{"key":"4053_CR54","doi-asserted-by":"publisher","first-page":"9556","DOI":"10.3390\/ijms21249556","volume":"21","author":"V Hlav\u00e1\u010d","year":"2020","unstructured":"Hlav\u00e1\u010d V, V\u00e1clav\u00edkov\u00e1 R, Brynychov\u00e1 V, Ko\u017eevnikovov\u00e1 R, Kope\u010dkov\u00e1 K, Vr\u00e1na D, et al. Role of genetic variation in ABC transporters in breast cancer prognosis and therapy response. Int J Mol Sci. 2020;21:9556.","journal-title":"Int J Mol Sci"},{"key":"4053_CR55","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4048\/jbc.2023.26.e1","volume":"26","author":"S Li","year":"2023","unstructured":"Li S, Lee W, Heo W, Son HY, Her Y, Kim JI, et al. AKR1C2 promotes metastasis and regulates the molecular features of luminal androgen receptor subtype in triple negative breast cancer cells. J Breast Cancer. 2023;26:60\u201376.","journal-title":"J Breast Cancer"},{"key":"4053_CR56","doi-asserted-by":"publisher","first-page":"e0234191","DOI":"10.1371\/journal.pone.0234191","volume":"15","author":"AS Hamy","year":"2020","unstructured":"Hamy AS, Darrigues L, Laas E, De Croze D, Topciu L, Lam GT, et al. Prognostic value of the residual cancer burden index according to breast cancer subtype: validation on a cohort of BC patients treated by neoadjuvant chemotherapy. PLoS One. 2020;15:e0234191.","journal-title":"PLoS One"},{"key":"4053_CR57","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","volume":"23","author":"C Yau","year":"2022","unstructured":"Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022;23:149\u201360.","journal-title":"Lancet Oncol"},{"key":"4053_CR58","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1158\/1078-0432.CCR-17-1912","volume":"24","author":"I Echavarria","year":"2018","unstructured":"Echavarria I, L\u00f3pez-Tarruella S, Picornell A, Garc\u00eda-Saenz J, Jerez Y, Hoadley K, et al. Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann\u2019s refined classification. Clin Cancer Res. 2018;24:1845\u201352.","journal-title":"Clin Cancer Res"},{"key":"4053_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082194","volume":"15","author":"W Zhang","year":"2023","unstructured":"Zhang W, Li E, Wang L, Lehmann BD, Chen XS. Transcriptome meta-analysis of triple-negative breast cancer response to neoadjuvant chemotherapy. Cancers (Basel). 2023;15:2194.","journal-title":"Cancers (Basel)"},{"key":"4053_CR60","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s13353-024-00876-x","volume":"66","author":"S Supplitt","year":"2025","unstructured":"Supplitt S, Karpinski P, Sasiadek M, Laczmanski L, Kujawa D, Matkowski R, et al. The analysis of transcriptomic signature of TNBC-searching for the potential RNA-based predictive biomarkers to determine the chemotherapy sensitivity. J Appl Genet. 2025;66:171\u201382.","journal-title":"J Appl Genet"},{"key":"4053_CR61","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1200\/JCO.23.00435","volume":"41","author":"JK Litton","year":"2023","unstructured":"Litton JK, Regan MM, Pusztai L, Rugo HS, Tolaney SM, Garrett-Mayer E, et al. Standardized definitions for efficacy end points in neoadjuvant breast cancer clinical trials: NeoSTEEP. J Clin Oncol. 2023;41:4433\u201342.","journal-title":"J Clin Oncol"},{"key":"4053_CR62","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ccell.2023.12.015","volume":"42","author":"KH Kim","year":"2024","unstructured":"Kim KH, Migliozzi S, Koo H, Hong JH, Park SM, Kim S, et al. Integrated proteogenomic characterization of glioblastoma evolution. Cancer Cell. 2024;42:358-377.e358.","journal-title":"Cancer Cell"},{"key":"4053_CR63","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4053_CR64","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1074\/mcp.TIR118.000943","volume":"18","author":"K Krug","year":"2019","unstructured":"Krug K, Mertins P, Zhang B, Hornbeck P, Raju R, Ahmad R, et al. A curated resource for phosphosite-specific signature analysis. Mol Cell Proteomics. 2019;18:576\u201393.","journal-title":"Mol Cell Proteomics"},{"key":"4053_CR65","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108\u201312.","journal-title":"Nature"},{"key":"4053_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"key":"4053_CR67","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160\u20137.","journal-title":"J Clin Oncol"},{"key":"4053_CR68","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/1471-2105-11-367","volume":"11","author":"R Gaujoux","year":"2010","unstructured":"Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. BMC Bioinformatics. 2010;11:367.","journal-title":"BMC Bioinformatics"},{"key":"4053_CR69","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1158\/1538-7445.AM2023-178","volume":"83","author":"WJ Ryu","year":"2023","unstructured":"Ryu WJ, Park S, Lee JD, Hwang Y, Jo S, Yong KT, et al. Abstract 178: establishment of patient-derived organoid of breast cancer. Cancer Res. 2023;83:178\u2013178.","journal-title":"Cancer Res"},{"key":"4053_CR70","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1038\/s41596-020-00474-1","volume":"16","author":"JF Dekkers","year":"2021","unstructured":"Dekkers JF, van Vliet EJ, Sachs N, Rosenbluth JM, Kopper O, Rebel HG, et al. Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids. Nat Protoc. 2021;16:1936\u201365.","journal-title":"Nat Protoc"},{"key":"4053_CR71","unstructured":"Lee DK KM, Hwang Y, Kim S-G, Ryu W-J, Kim G-U, Yun HM, Park SY, Lee JD, Han HJ, Kim GM, Kim K-H, Park JB, Kim MJ, Koo JS, Kim JY, Park HS, Kim SI, Gee HY, Park S, Sohn J: Triple-negative breast cancer WES. PRJNA1422845. 2026. https:\/\/www.ncbi.nlm.nih.gov\/bioproject\/?term=PRJNA1422845."},{"key":"4053_CR72","unstructured":"Lee DK KM, Hwang Y, Kim S-G, Ryu W-J, Kim G-U, Yun HM, Park SY, Lee JD, Han HJ, Kim GM, Kim K-H, Park JB, Kim MJ, Koo JS, Kim JY, Park HS, Kim SI, Gee HY, Park S, Sohn J: Triple-negative breast cancer RNA sequencing. PRJNA1422844. 2026. https:\/\/www.ncbi.nlm.nih.gov\/bioproject\/?term=PRJNA1422844."},{"key":"4053_CR73","unstructured":"Lee DK KM, Hwang Y, Kim S-G, Ryu W-J, Kim G-U, Yun HM, Park SY, Lee JD, Han HJ, Kim GM, Kim K-H, Park JB, Kim MJ, Koo JS, Kim JY, Park HS, Kim SI, Gee HY, Park S, Sohn J: Triple-negative breast cancer proteome. PDC000695. 2026. https:\/\/pdc.cancer.gov\/pdc\/study\/PDC000695."},{"key":"4053_CR74","unstructured":"Lee DK KM, Hwang Y, Kim S-G, Ryu W-J, Kim G-U, Yun HM, Park SY, Lee JD, Han HJ, Kim GM, Kim K-H, Park JB, Kim MJ, Koo JS, Kim JY, Park HS, Kim SI, Gee HY, Park S, Sohn J: Triple-negative breast cancer phosphoproteome. PDC000696. 2026. https:\/\/pdc.cancer.gov\/pdc\/study\/PDC000696."}],"container-title":["Genome Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13059-026-04053-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13059-026-04053-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13059-026-04053-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:02:26Z","timestamp":1776117746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13059-026-04053-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4053"],"URL":"https:\/\/doi.org\/10.1186\/s13059-026-04053-7","relation":{},"ISSN":["1474-760X"],"issn-type":[{"value":"1474-760X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board (IRB) of Severance Hospital (IRB Number: 4\u20132020-0473) and adhered to the Declaration of Helsinki and Good Clinical Practice guidelines. The informed consents were obtained from all enrolled patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}